Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.33 |
| ▸ | CBFB | Q13951 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847213 | 0.86 | SMN1; SMN2 (0.37) | ADORA2AADORA1 | |
| SCHEMBL8140217 | 0.76 | ADORA2A (0.50) | ADORA2AADORA1METAP1SLC2A1CBFB | |
| SCHEMBL4853815 | 0.71 | LMNA (0.35) | METAP1SYKFLT3AURKB | |
| SCHEMBL4856808 | 0.69 | SMN1; SMN2 (0.53) | — | |
| SCHEMBL4847192 | 0.68 | ADORA2A (0.44) | ADORA2AADORA1METAP1SLC2A1 | |
| SCHEMBL4854423 | 0.67 | ADORA2A (0.42) | ADORA2AADORA1METAP1SLC2A1 | |
| SCHEMBL4735939 | 0.67 | ADORA2A (0.50) | ADORA2AADORA1METAP1SLC2A1ADORA2B | |
| SCHEMBL4736973 | 0.67 | CCR1 (0.51) | ADORA2AADORA1ADORA3METAP1SLC2A1 | |
| SCHEMBL4854167 | 0.66 | ATM (0.46) | ADORA2AADORA1SLC2A1NPC1RAB9A | |
| SCHEMBL12192256 | 0.64 | TRPM8 (0.56) | ADORA2AADORA1ADORA3METAP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | claimed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | claimed |
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828329-B2 | Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders | NEUROGEN CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | CHRNA7, CHRNA4, GABRA6 | ADORA2A 81/4885ADORA1 109/4885ADORA3 169/4885 |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | GABRA4, GABRA6, GABRG2 | ADORA2A 73/4885ADORA1 80/4885ADORA3 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.